Impact of atopic status, prior omalizumab use and baseline blood eosinophil count alone and in combination with total serum IgE on maintenance OCS reduction outcomes in patients with severe asthma treated with mepolizumab in the REALITI-A study
Title:
Impact of atopic status, prior omalizumab use and baseline blood eosinophil count alone and in combination with total serum IgE on maintenance OCS reduction outcomes in patients with severe asthma treated with mepolizumab in the REALITI-A study
Author:
Liu, M. Chaudhuri, R. Chupp, G. Heaney, L.G. Lee, J.K. Pilette, C. Brusselle, G. Alfonso-Cristancho, R. Zhang, L. Howarth, P. Kumar, A.